Group 1 - On January 29, Haoyuan Pharmaceutical's stock fell by 5.68%, with a trading volume of 588 million yuan [1] - The financing data shows that on the same day, Haoyuan Pharmaceutical had a financing purchase amount of 64.30 million yuan and a net financing purchase of 8.90 million yuan [1] - As of January 29, the total balance of margin trading for Haoyuan Pharmaceutical was 631 million yuan, which accounts for 4.02% of its circulating market value [1] Group 2 - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [2] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42% [2] - For the period from January to September 2025, Haoyuan Pharmaceutical achieved an operating income of 2.06 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, up by 65.09% [2] Group 3 - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 160 million yuan in dividends, with 120 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders of Haoyuan Pharmaceutical include Hong Kong Central Clearing Limited as the second-largest shareholder, increasing its holdings by 2.35 million shares [3] - New institutional shareholders include China Europe Medical Innovation Stock A, holding 2.21 million shares, and Huatai-PineBridge Healthcare Mixed Fund, holding 1.41 million shares [3]

Core Viewpoint - The company is committed to a global development strategy, with operations spanning multiple countries and regions, while maintaining a low revenue share from the European single market [1] Group 1: Business Strategy - The company adopts a differentiated sales model to meet the varying needs of different products, regions, and customer types, primarily utilizing direct sales supplemented by distribution for front-end molecular building blocks, tool compounds, and biochemical reagents [1] - For back-end active pharmaceutical ingredients (APIs) and intermediates, as well as formulation business, direct sales serve as the core approach, with distribution acting as a supplementary channel [1] Group 2: Market Investment - In recent years, the company has increased its investment in the European market, having established a European business center that is now officially operational [1]

Core Viewpoint - The stock price of Haoyuan Pharmaceutical has shown fluctuations, with a recent decline of 2.02% and a year-to-date increase of 16.01%, indicating volatility in market performance [1][2]. Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of small molecule drug discovery, including molecular building blocks and tool compounds [2]. - The company provides products and technical services for global pharmaceutical enterprises and research institutions, covering the entire process from drug discovery to the large-scale production of active pharmaceutical ingredients and intermediates [2]. Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, reflecting a significant increase of 65.09% [2]. - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, with an average of 17,647 circulating shares per person, an increase of 6.77% [2]. - Notable shareholders include Hong Kong Central Clearing Limited, which holds 8.6068 million shares, and several mutual funds that have increased their holdings [3].

Core Viewpoint - The stock price of Haoyuan Pharmaceutical has shown significant growth, with a year-to-date increase of 20.66% and a recent surge in trading activity, indicating strong investor interest and confidence in the company's performance [2][3]. Group 1: Stock Performance - As of January 19, Haoyuan Pharmaceutical's stock rose by 2.01%, reaching 86.97 CNY per share, with a trading volume of 86.33 million CNY and a turnover rate of 0.48% [1]. - The company has experienced a 20.66% increase in stock price this year, with a 5.41% rise in the last five trading days and a 23.00% increase over the past 20 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical reported a revenue of 2.059 billion CNY, reflecting a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million CNY, which is a 65.09% increase [2]. - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents, accounting for 68.97% of total revenue, with product sales contributing 63.42% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, while the average circulating shares per person increased by 6.77% to 17,647 shares [2]. - The company has distributed a total of 160 million CNY in dividends since its A-share listing, with 120 million CNY distributed over the past three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 8.6068 million shares, an increase of 2.3457 million shares from the previous period [3]. - New institutional shareholders include China Europe Medical Innovation Stock A, holding 2.2063 million shares, and Huatai-PineBridge Healthcare Mixed Fund, holding 1.4103 million shares [3].

Core Viewpoint - Haoyuan Pharmaceutical's stock has shown a positive trend with an 11.90% increase year-to-date and a 7.82% increase over the last five trading days, indicating strong market performance and investor interest [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents (68.97%), with product sales contributing 63.42%, raw materials and intermediates 30.46%, technical services 5.55%, and others 0.57% [1] Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, reflecting a 65.09% increase [2] - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, while the average circulating shares per person increased by 6.77% to 17,647 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 2.3457 million shares, and new entrants such as Huatai-PineBridge Healthcare Mixed Fund and China Europe Medical Innovation Stock A [3]

Core Viewpoint - The company, Haoyuan Pharmaceutical, asserts its competitive advantage in the tool compound business and strong international influence, while also integrating its recombinant protein and biochemical reagent businesses to enhance resource efficiency and market synergy [1] Business Overview - The tool compound and biochemical reagent segment is presented as a combined performance metric in financial disclosures, indicating a strategic alignment of these business areas [1] - The company has committed to increasing research and development in the biochemical reagent sector, with over 23,000 types of biopolymer products, including recombinant proteins, antibodies, and enzymes, developed by the end of Q3 2025 [1]

Core Viewpoint - Haoyuan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 116.75%, indicating strong market performance and investor interest [1][2]. Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2]. - The company's main business revenue composition includes molecular building blocks and tool compounds (68.97%), with product sales contributing 63.42%, raw materials and intermediates at 30.46%, and technical services at 5.55% [2]. Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, while the net profit attributable to shareholders was 237 million yuan, up 65.09% year-on-year [2]. - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, with an average of 17,647 circulating shares per shareholder, an increase of 6.77% [2]. - Notable institutional shareholders include Hong Kong Central Clearing Limited, which holds 8.6068 million shares, and several funds that have increased their holdings [3].

Core Insights - On November 14, Haoyuan Pharmaceutical experienced a decline of 3.54% with a trading volume of 242 million yuan [1] - The company reported a financing buy-in of 32.97 million yuan and a net financing buy of 6.87 million yuan on the same day [1] Financing Overview - As of November 14, the total financing and securities balance for Haoyuan Pharmaceutical was 592 million yuan [1] - The financing balance of 591 million yuan accounts for 3.61% of the circulating market value, indicating a high level compared to the past year [1] - The company had a low securities lending balance of 96.21 million yuan, below the 50th percentile of the past year [1] Company Profile - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main revenue sources include molecular building blocks and tool compounds (68.97%), with product sales contributing 63.42% and raw materials and intermediates accounting for 30.46% [2] - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit of 237 million yuan, up 65.09% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable increases in holdings [3]

Core Viewpoint - Haoyuan Pharmaceutical's stock rose by 5.01% to 80.35 CNY per share, with a trading volume of 259 million CNY and a market capitalization of 17.042 billion CNY as of November 13 [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021 [1] - The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main revenue composition includes: molecular building blocks, tool compounds, and biochemical reagents (68.97%); product sales (63.42%); APIs and intermediates, formulations (30.46%); technical services (5.55%); and other (0.57%) [1] Fund Holdings - Hongta Hongtu Fund has a significant holding in Haoyuan Pharmaceutical, with its Hongta Hongtu Medical Selected Stock Fund A (020331) reducing its stake by 4,000 shares to hold 9,000 shares, representing 5.58% of the fund's net value [2] - The fund has achieved a year-to-date return of 33.15%, ranking 1506 out of 4216 in its category, and a one-year return of 18.94%, ranking 2064 out of 3951 [2] Fund Manager Information - The fund manager of Hongta Hongtu Medical Selected Stock Fund A is Cao Yang, who has been in the position for 2 years and 63 days [3] - The total asset size of the fund is 13.3331 million CNY, with the best return during his tenure being 30.03% and the worst being -33.52% [3]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported better-than-expected performance for Q3 2025, with revenue of 7.48 billion yuan, representing a year-over-year growth of 32.76%, and a net profit of 0.85 billion yuan, up 16.39% year-over-year [1] - The strong performance is attributed to high growth in the front-end business, which generated 5.4 billion yuan in revenue, a year-over-year increase of over 36% [1][2] - The company has improved efficiency and strictly controlled costs, contributing to the positive financial results [1] Summary by Sections Front-end Business - The front-end business, including tool compounds and biochemical reagents, serves as the primary growth engine, maintaining high revenue growth [2] - The molecular building blocks segment has seen a significant increase in customer and order numbers, marking it as a secondary growth engine [2] - As of June 2025, the company has a reserve of over 52,000 tool compounds and biochemical reagents, and approximately 95,000 molecular building blocks, creating a comprehensive compound library [2] Back-end Business - The back-end business, which includes APIs, intermediates, and formulations, has a strong order backlog exceeding 5.9 billion yuan, reflecting a year-over-year growth of 40.1% [3] - The company is enhancing its competitive edge in the XDC segment and has established a strategic layout across Shanghai, Ma'anshan, and Chongqing [3] Financial Forecast and Valuation - The company’s net profit forecasts for 2025 and 2026 have been adjusted to 2.88 billion yuan and 4.00 billion yuan, respectively, with a new forecast for 2027 set at 5.19 billion yuan [3] - The estimated EPS for 2025, 2026, and 2027 are 1.36 yuan, 1.89 yuan, and 2.45 yuan, respectively, with corresponding P/E ratios of 62, 45, and 35 [3]